| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918542 | Radiotherapy and Oncology | 2014 | 9 Pages |
Abstract
Targeting the PI3K/mTOR pathway substantially reduces mitochondrial oxygen consumption thereby reducing tumor hypoxia. These alterations in tumor hypoxia should be considered in the design of clinical trials using PI3K/mTOR inhibitors, particularly in conjunction with radiotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Catherine J. Kelly, Kamila Hussien, Emmanouil Fokas, Pavitra Kannan, Rebecca J. Shipley, Thomas M. Ashton, Michael Stratford, Natalie Pearson, Ruth J. Muschel,